Medincell SA banner

Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 23.8 EUR 2.76% Market Closed
Market Cap: €854.7m

Medincell SA
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Medincell SA
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Medincell SA
PAR:MEDCL
Free Cash Flow
-€18.9m
CAGR 3-Years
5%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Sanofi SA
PAR:SAN
Free Cash Flow
€10.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Free Cash Flow
€827.9m
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
19%
Vetoquinol SA
PAR:VETO
Free Cash Flow
€49.3m
CAGR 3-Years
42%
CAGR 5-Years
-5%
CAGR 10-Years
7%
Virbac SA
PAR:VIRP
Free Cash Flow
€96.9m
CAGR 3-Years
29%
CAGR 5-Years
1%
CAGR 10-Years
36%
Boiron SA
PAR:BOI
Free Cash Flow
€37.3m
CAGR 3-Years
-8%
CAGR 5-Years
-8%
CAGR 10-Years
-10%
No Stocks Found

Medincell SA
Glance View

Market Cap
854.7m EUR
Industry
Pharmaceuticals

MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.

MEDCL Intrinsic Value
25.74 EUR
Undervaluation 8%
Intrinsic Value
Price €23.8

See Also

What is Medincell SA's Free Cash Flow?
Free Cash Flow
-18.9m EUR

Based on the financial report for Sep 30, 2025, Medincell SA's Free Cash Flow amounts to -18.9m EUR.

What is Medincell SA's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-12%

The average annual Free Cash Flow growth rates for Medincell SA have been 5% over the past three years , -12% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett